Patents by Inventor John Koren

John Koren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSP90 activator AHA1 drives production of pathological tau aggregates
    Patent number: 11931373
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 19, 2024
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    Publication number: 20220241309
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Hsp90 activator Aha1 drives production of pathological tau aggregates
    Patent number: 11318155
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 3, 2022
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair
  • THE HSP90 ACTIVATOR AHA1 DRIVES PRODUCTION OF PATHOLOGICAL TAU AGGREGATES
    Publication number: 20210128597
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: February 23, 2018
    Publication date: May 6, 2021
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair
  • GRP94 INHIBITORS TO TREAT STEROID-INDUCED OCULAR HYPERTENSIONS AND GLAUCOMAS
    Publication number: 20210030719
    Abstract: A method and composition for preventing, reducing, or treating steroid-induced ocular hypertension and steroid-induced glaucoma using a selective Grp94 inhibitor is presented. The Grp94-selective inhibitor can include methyl 2-(2-(1(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (4-Br—BnIm) or a derivative thereof. The Grp94-selective inhibitor can be administered prior to, during, or after administration of a steroid to the patient.
    Type: Application
    Filed: February 22, 2019
    Publication date: February 4, 2021
    Inventors: Chad A. DICKEY (Deceased), John KOREN, Laura J. BLAIR, Brian S.J. BLAGG, Ricardo A. CORDOVA, Zheying SUN
  • RATIONAL COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20180280397
    Abstract: The disclosure provides methods of using inhibitors of chaperone proteins, such as HSP90 inhibitors, in combination with agents that increase proteotoxic stress on tumor cells or agents that induce a biochemical rewiring of the chaperome. The proteotoxic agents are administered prior to administration of the chaperone proteins to achieve synergistic activity.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Inventors: Gabriela Chiosis, Tony Taldone, Liza Shrestha, John Koren, Erica M. Gomes-DaGama, Anna Rodina